Drug
Allo 329
Allo 329: highest development phase Phase 1, developed by Allogene Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Allogene Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALLO-329 NCT07085104 | Phase 1 | Systemic Lupus Erythematosus (With and Without Nephritis) |
Latest
No recent events.
Follow Allo 329 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.